Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tolbutamide

FDA-approved product (tablet, oral), marketed as Orinase, Tolbutamide, Orinase Diagnostic.

Registered studies
34
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tolbutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas; Tests for diabetes
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tolbutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tolbutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

    NCT02182401 · start 2009-07

    Registered record
    Registry ID
    NCT02182401
    Conditions
    Healthy
    Interventions
    BI 207127 NA; BI 201335 NA; Midazolam; Tolbutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-07
    Completion
    Not recorded
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 207127 NA; BI 201335 NA; Midazolam; Tolbutamide
    PhasePhase 1
    Registry statusTerminated

  • AZD2066 Cocktail Study

    NCT00930306 · start 2009-06

    Registered record
    Registry ID
    NCT00930306
    Conditions
    Chronic Pain
    Interventions
    AZD2066; Caffeine; Tolbutamide; Omeprazole Tablet, 20 mg; Midazolam Tablet, 7.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2009-09
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pain
    InterventionAZD2066; Caffeine; Tolbutamide; Omeprazole Tablet, 20 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

    NCT00741468 · start 2008-07

    Registered record
    Registry ID
    NCT00741468
    Conditions
    Drug Interactions
    Interventions
    Proellex; CYP1A2 probe; CYP2C9 probe; CYP2C19 probe; CYP2D6 probe; CYP3A4 probe
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-10
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interactions
    InterventionProellex; CYP1A2 probe; CYP2C9 probe; CYP2C19 probe +2 more
    PhasePhase 1
    Registry statusCompleted

  • Blockade of Vascular Potassium Channels During Human Endotoxemia

    NCT00185003 · start 2003-01

    Registered record
    Registry ID
    NCT00185003
    Conditions
    Endotoxemia
    Interventions
    endotoxin; Potassium channel blockers: TEA, Quinin, Tolbutamide; L-NMMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-01
    Completion
    2005-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndotoxemia
    Interventionendotoxin; Potassium channel blockers: TEA, Quinin, Tolbutamide; L-NMMA
    PhasePhase 1
    Registry statusCompleted